Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5468-5475

  Chou, Ho Yuan ^a,b   Lin, Xi Zhang ^c   Pan, Wen Yu ^a,d   Wu, Ping Yi ^b   Chang, Chia Ming ^b   Lin, Tsai Yu ^e   Shen, Hsin Hsin ^e   Tao, Mi Hua ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B CORE ANTIBODY; HEPATITIS B VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; HEPATITIS B SURFACE ANTIGEN; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; C57BL 10 MOUSE; CELL ACTIVATION; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HAPLOTYPE; HEAT SENSITIVITY; HUMORAL IMMUNITY; HYDROGEL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG RESISTANCE; GENETICS; HELPER CELL; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METHODOLOGY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DENDRITIC CELLS; DRUG RESISTANCE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYDROGEL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION;

EID: 78149488427     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001875     Document Type: Article

References (61)

1. Lok, A. S. 2002. Chronic hepatitis B. N. Engl. J. Med. 346:1682-1683.
2. Ganem, D., and A. M. Prince. 2004. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350:1118-1129.
3. Zanetti, A. R., P. Van Damme, and D. Shouval. 2008. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26:6266-6273.
4. Chen, D. S. 2009. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J. Hepatol. 50:805-816.
5. Chen, H. L., M. H. Chang, Y. H. Ni, H. Y. Hsu, P. I. Lee, C. Y. Lee, and D. S. Chen. 1996. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276:906-908.
6. Viviani, S., A. Jack, A. J. Hall, N. Maine, M. Mendy, R. Montesano, and H. C. Whittle. 1999. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17:2946-2950.
7. Chang, M. H., C. J. Chen, M. S. Lai, H. M. Hsu, T. C. Wu, M. S. Kong, D. C. Liang, W. Y. Shau, D. S. Chen; Taiwan Childhood Hepatoma Study Group. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1855-1859.
8. Dienstag, J. L., B. G. Werner, B. F. Polk, D. R. Snydman, D. E. Craven, R. Platt, C. S. Crumpacker, R. Ouellet-Hellstrom, and G. F. Grady. 1984. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann. Intern. Med. 101:34-40.
9. Crosnier, J., P. Jungers, A. M. Couroucé, A. Laplanche, E. Benhamou, F. Degos, B. Lacour, P. Prunet, Y. Cerisier, and P. Guesry. 1981. Randomised placebocontrolled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet 1:797-800.
10. Stevens, C. E., H. J. Alter, P. E. Taylor, E. A. Zang, E. J. Harley, and W. Szmuness. 1984. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N. Engl. J. Med. 311:496-501.
11. Milich, D. R., and G. G. Leroux-Roels. 2003. Immunogenetics of the response to HBsAg vaccination. Autoimmun. Rev. 2:248-257.
12. Egea, E., A. Iglesias, M. Salazar, C. Morimoto, M. S. Kruskall, Z. Awdeh, S. F. Schlossman, C. A. Alper, and E. J. Yunis. 1991. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 173:531-538.
13. Vingerhoets, J., G. Vanham, L. Kestens, G. Penne, G. Leroux-Roels, and P. Gigase. 1994. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol. Lett. 39:163-168.
14. Chedid, M. G., H. Deulofeut, D. E. Yunis, M. L. Lara-Marquez, M. Salazar, R. Deulofeut, Z. Awdeh, C. A. Alper, and E. J. Yunis. 1997. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum. Immunol. 58:42-51.
15. Larsen, C. E., J. Xu, S. Lee, D. P. Dubey, G. Uko, E. J. Yunis, and C. A. Alper. 2000. Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine 18:3021-3030.
16. Goncalves, L., B. Albarran, S. Salmen, L. Borges, H. Fields, H. Montes, A. Soyano, Y. Diaz, and L. Berrueta. 2004. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326:20-28.
17. Metcalf, D. 1986. The molecular biology and functions of the granulocytemacrophage colony-stimulating factors. Blood 67:257-267.
18. Gasson, J. C. 1991. Molecular physiology of granulocyte-macrophage colonystimulating factor. Blood 77:1131-1145.
19. Morrissey, P. J., L. Bressler, L. S. Park, A. Alpert, and S. Gillis. 1987. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. 139:1113-1119.
20. Warren, T. L., and G. J. Weiner. 2000. Uses of granulocyte-macrophage colonystimulating factor in vaccine development. Curr. Opin. Hematol. 7:168-173.
21. Chang, D. Z., W. Lomazow, C. Joy Somberg, R. Stan, and M. A. Perales. 2004. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9:207-215.
22. Kim, M. J., A. N. Nafziger, C. D. Harro, H. L. Keyserling, K. M. Ramsey, G. L. Drusano, and J. S. Bertino, Jr. 2003. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 21:1174-1179.
23. Kapoor, D., S. R. Aggarwal, N. P. Singh, V. Thakur, and S. K. Sarin. 1999. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J. Viral Hepat. 6:405-409.
24. Sudhagar, K., S. Chandrasekar, M. S. Rao, and R. Ravichandran. 1999. Effect of granulocyte macrophage colony stimulating factor on hepatitis-B vaccination in haemodialysis patients. J. Assoc. Physicians India 47:602-604.
25. Anandh, U., B. Bastani, and S. Ballal. 2000. Granulocyte-macrophage colonystimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am. J. Nephrol. 20:53-56.
26. Evans, T. G., M. Schiff, B. Graves, J. Agosti, M. L. Barritt, D. Garner, and J. L. Holley. 2000. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 54:138-142.
27. Jha, R., S. Lakhtakia, M. A. Jaleel, G. Narayan, and K. Hemlatha. 2001. Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders. Ren. Fail. 23:629-636.
28. Singh, N. P., S. K. Mandal, A. Thakur, D. Kapoor, S. Anuradha, A. Prakash, R. Kohli, and S. K. Agarwal. 2003. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure-results of a prospective, randomized trial. Ren. Fail. 25:255-266.
29. Cruciani, M., C. Mengoli, G. Serpelloni, R. Mazzi, O. Bosco, and M. Malena. 2007. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 25:709-718.
30. Tao, M. H., and R. Levy. 1993. Idiotype/granulocyte-macrophage colonystimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758.
31. Peng, K. T., C. F. Chen, I. M. Chu, Y. M. Li, W. H. Hsu, R. W. Hsu, and P. J. Chang. 2010. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles. Biomaterials 31:5227-5236.
32. Milich, D. R., and F. V. Chisari. 1982. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg. J. Immunol. 129:320-325.
33. Hsieh, J. H., K. Y. Shih, H. F. Kung, M. Shiang, L. Y. Lee, M. H. Meng, C. C. Chang, H. M. Lin, S. C. Shih, S. Y. Lee, et al. 1988. Controlled fed-batch fermentation of recombinant Saccharomyces cerevisiae to produce hepatitis B surface antigen. Biotechnol. Bioeng. 32:334-340.
34. Chow, Y. H., B. L. Chiang, Y. L. Lee, W. K. Chi, W. C. Lin, Y. T. Chen, and M. H. Tao. 1998. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. 160:1320-1329.
35. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rössner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77-92.
36. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
37. Craven, D. E., Z. L. Awdeh, L. M. Kunches, E. J. Yunis, J. L. Dienstag, B. G. Werner, B. F. Polk, D. R. Syndman, R. Platt, C. S. Crumpacker, et al. 1986. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann. Intern. Med. 105:356-360.
38. Alper, C. A., M. S. Kruskall, D. Marcus-Bagley, D. E. Craven, A. J. Katz, S. J. Brink, J. L. Dienstag, Z. Awdeh, and E. J. Yunis. 1989. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321:708-712.
39. McDermott, A. B., J. N. Zuckerman, C. A. Sabin, S. G. Marsh, and J. A. Madrigal. 1997. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 50:8-14.
40. Desombere, I., A. Willems, and G. Leroux-Roels. 1998. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 51:593-604.
41. Stute, N., V. M. Santana, J. H. Rodman, M. J. Schell, J. N. Ihle, and W. E. Evans. 1992. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79:2849-2854.
42. Zentner, G. M., R. Rathi, C. Shih, J. C. McRea, M. H. Seo, H. Oh, B. G. Rhee, J. Mestecky, Z. Moldoveanu, M. Morgan, and S. Weitman. 2001. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release 72:203-215.
43. Cole, D. J., S. Gattoni-Celli, E. F. McClay, J. S. Metcalf, J. M. Brown, N. Nabavi, D. A. Newton, III, C. B. Woolhiser, M. C. Wilson, and J. N. Vournakis. 1997. Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosaminebased polymer matrix. Clin. Cancer Res. 3:867-873.
44. Nguyen, C. L., J. T. Bui, M. Demcheva, J. N. Vournakis, D. J. Cole, and W. E. Gillanders. 2001. Sustained release of granulocyte-macrophage colonystimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J. Immunother. 24:420-429.
45. Lang, R. A., D. Metcalf, R. A. Cuthbertson, I. Lyons, E. Stanley, A. Kelso, G. Kannourakis, D. J. Williamson, G. K. Klintworth, T. J. Gonda, et al. 1987. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 51:675-686.
46. Burke, B., A. Pridmore, N. Harraghy, A. Collick, J. Brown, and T. Mitchell. 2004. Transgenic mice showing inflammation-inducible overexpression of granulocyte macrophage colony-stimulating factor. Clin. Diagn. Lab. Immunol. 11:588-598.
47. Bronte, V., E. Apolloni, A. Cabrelle, R. Ronca, P. Serafini, P. Zamboni, N. P. Restifo, and P. Zanovello. 2000. Identification of a CD11b (+)/Gr-1 (+)/CD31 (+) myeloid progenitor capable of activating or suppressing CD8 (+) T cells. Blood 96:3838-3846.
48. Serafini, P., R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello. 2004. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64:6337-6343.
49. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25:2546-2553.
50. Chiou, S. S., K. Yamauchi, T. Nakanishi, and H. Obata. 1988. Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology 64:545-550.
51. Shokrgozar, M. A., and F. Shokri. 2001. Enumeration of hepatitis B surface antigenspecific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 104:75-79.
52. Kurose, K., S. M. Akbar, K. Yamamoto, and M. Onji. 1997. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 92:494-500.
53. Goldwater, P. N. 1997. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 15:353-356.
54. Fazle Akbar, S. M., S. Furukawa, O. Yoshida, Y. Hiasa, N. Horiike, and M. Onji. 2007. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J. Hepatol. 47:60-66.
55. Milich, D. R., M. K. McNamara, A. McLachlan, G. B. Thornton, and F. V. Chisari. 1985. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc. Natl. Acad. Sci. USA 82:8168-8172.
56. Milich, D. R., G. B. Thornton, A. R. Neurath, S. B. Kent, M. L. Michel, P. Tiollais, and F. V. Chisari. 1985. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228:1195-1199.
57. Zuckerman, J. N., A. J. Zuckerman, I. Symington, W. Du, A. Williams, B. Dickson, M. D. Young; UK Hepacare Study Group. 2001. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 34:798-802.
58. Bertino, J. S., Jr., P. Tirrell, R. N. Greenberg, H. L. Keyserling, G. A. Poland, D. Gump, M. L. Kumar, and K. Ramsey. 1997. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J. Infect. Dis. 175:678-681.
59. 2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 15:1732-1736.
60. Milich, D. R., J. L. Hughes, A. McLachlan, K. E. Langley, G. B. Thornton, and J. E. Jones. 1990. Importance of subtype in the immune response to the pre-S (2) region of the hepatitis B surface antigen. I. T cell fine specificity. J. Immunol. 144:3535-3543.
61. Pai, S. S., R. D. Tilton, and T. M. Przybycien. 2009. Poly (ethylene glycol) - modified proteins: implications for poly (lactide-co-glycolide)-based microsphere delivery. AAPS J. 11:88-98.